ALFA USA News
Straight from the SEC filing
Every SEC filing by Ultragenyx Pharmaceutical Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (14 Oct 2026). Not a valuation or a recommendation.
Up 9.6% over the last month ($13.61 on 14 Sep → $14.92 on 13 Oct). Daily closing prices. Source: Yahoo Finance.
| 14 Sep | $13.61 |
|---|---|
| 15 Sep | $13.07 |
| 16 Sep | $12.88 |
| 17 Sep | $14.50 |
| 18 Sep | $14.51 |
| 21 Sep | $14.65 |
| 22 Sep | $15.62 |
| 23 Sep | $14.88 |
| 24 Sep | $14.77 |
| 25 Sep | $14.50 |
| 28 Sep | $14.41 |
| 29 Sep | $15.32 |
| 30 Sep | $15.03 |
| 1 Oct | $14.75 |
| 2 Oct | $15.22 |
| 5 Oct | $14.50 |
| 6 Oct | $14.46 |
| 7 Oct | $14.89 |
| 8 Oct | $15.29 |
| 9 Oct | $15.48 |
| 12 Oct | $15.30 |
| 13 Oct | $14.92 |
Ultragenyx Pharmaceutical Inc. (RARE) enters agreement to divest its Rare Pediatric Disease Priority Review Voucher for $203 million following FDA approval.
Ultragenyx Pharmaceutical Inc. agrees to sell its Rare Pediatric Disease Priority Review Voucher for $210 million, following the FDA approval of GENGLYCOS treatment.
Track Ultragenyx Pharmaceutical Inc. live
Get the next Ultragenyx Pharmaceutical Inc. SEC filing seconds after it lands.
